Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada.

ABSTRACT:

Introduction

The expensive modern therapeutic regimens for advanced lung cancer (LC) stages have been recently approved. We evaluated whether low-dose computed tomography (LDCT) LC screening of high-risk Albertans is cost saving.

Methods

We used a decision analytical modeling technique with a health system perspective and a time horizon of 3 years to compare benefits associated with reduced health service utilization (HSU) from earlier diagnosis to the costs of screening. Using patient-level data, HSU costs by stage of disease were estimated for patients with LC, including inpatient, outpatient, and physician services, and costs for prescription drugs and cancer treatments.

Results

Of 101,000 people aged 55 to 74 years eligible for screening, an estimated 88,476 scans

SUBMITTER: Thanh NX 

PROVIDER: S-EPMC9234227 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature